Chemoradiation in Nasopharyngeal Carcinoma: A 6-Year Experience in Tehran Cancer Institute

  • Bita Kalaghchi Cancer Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran. AND Department of Radiation Oncology, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Ali Kazemian Department of Radiation Oncology, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Farnaz Amouzegar Hashemi Department of Radiation Oncology, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Mehdi Aghili Department of Radiation Oncology, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Farshid Farhan Department of Radiation Oncology, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Peiman Haddad Department of Radiation Oncology, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
Keywords: Nasopharyngeal neoplasms, Radiotherapy, Chemotherapy

Abstract

To determine the addition of value of neoadjuvant, concurrent and adjuvant chemotherapy to radiation in the treatment of nasopharyngeal carcinoma with regard to the overall survival (OS) and disease free survival (DFS) within a six year period in Tehran cancer institute. Files of all patients with nasopharyngeal carcinoma treated by radiotherapy with or without concurrent chemotherapy in a curative setting in Tehran cancer institute during the period of 1999-2005 were retrospectively reviewed.. A total of 103 patients with nasopharyngeal carcinoma had been treated during the study period with radiotherapy or chemoradiotherapy in our institute. There were 29 (28.2%) females and 74 (71.8%) males. The median age at the time of radiotherapy was 47 years old (range 9-75 years). The patients were followed 2 to 76 months with a median follow-up of 14 months. Time of first recurrence after treatment was 3-44 months with a median of 10 months.. Survival in 2 groups of patients treated with radiotherapy alone or chemoradiation did not have a significant difference (P>0.1). Two-year survival in patients treated with or without adjuvant chemotherapy and had local recurrence after treatment did not have significant difference (P>0.1). Two-year survival in patients with or without local recurrence after treatment did not have significant difference (P>0.1). A beneficial affect or a survival benefit of adjuvant/neoadjuvant chemotherapy and concurrent chemoradiation was not observed in Iranian patients.

References

Kingdom of Saudi Arabia, Ministry of Health, Nationaln Cancer Registry [Online]. Cancer Incidence Report, Saudi Arabia, 1999-2000. 2004 [cited 2011 Mar 1]; Available from:URL:www.kfshrc.edu.sa/oncology/files/ncr99_00.pdf

Chan AT, Teo PM, Huang DP. Pathogenesis and treatment of nasopharyngeal carcinoma. Semin Oncol 2004;31(6):794-801.

Jeyakumar A, Brickman TM, Jeyakumar A, Doerr T. Review of nasopharyngeal carcinoma. Ear Nose Throat J 2006;85(3):168-70, 172-3, 184.

Lee RC, Ekaette E, Kelly KL, Craighead P, Newcomb C, Dunscombe P. Implications of cancer staging uncertainties in radiation therapy decisions. Med DecisMaking 2006;26(3):226-38.

Geara FB, Nasr E, Tucker SL, Brihi E, Zaytoun G, Hadi U, Salem Z, El Saghir N, Issa P, Shamseddine A. Nasopharyngeal cancer in the Middle East: experience of the American University of Beirut Medical Center. Int J Radiat Oncol Biol Phys 2005;61(5):1408-15.

Chua DT, Sham JS, Au GK, Choy D. Concomitant chemoirradiation for stage III-IV nasopharyngeal carcinoma in Chinese patients: results of a matched cohort analysis. Int J Radiat Oncol Biol Phys 2002;53(2):334-43.

How to Cite
1.
Kalaghchi B, Kazemian A, Amouzegar Hashemi F, Aghili M, Farhan F, Haddad P. Chemoradiation in Nasopharyngeal Carcinoma: A 6-Year Experience in Tehran Cancer Institute. Acta Med Iran. 49(1):49-53.
Section
Articles